ARGENX SE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 429.9 EUR | -0.12% |
|
+6.31% | +25.15% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.
Calendar
2024-07-16
- R&D Day
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
429.9
EUR
Average target price
455.5
EUR
Spread / Average Target
+5.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.15% | 27.69B | |
| +20.95% | 127B | |
| +23.00% | 116B | |
| -19.75% | 19.62B | |
| -16.57% | 16.26B | |
| -16.56% | 15.49B | |
| +11.19% | 14.81B | |
| -46.65% | 14.39B | |
| +57.74% | 14.11B | |
| +148.56% | 11.79B |
- Stock Market
- Equities
- ARGX Stock
- News argenx SE
- Stifel Raises Argenx Price Target to $500 From $485, Maintains Buy Rating
